Liposomal formulations of mistletoe produced by centrifugal technologies suitable for cancer therapy
Gero Leneweit(Abnoba (Germany)), Christoph Heyder(Abnoba (Germany)), Illya Fedotenko(Karlsruhe Institute of Technology), Maria de Fátima Cepa Matos(Utrecht University), Kristina Nilsson Ekdahl(Uppsala University), Yvonne Klapper(Karlsruhe Institute of Technology), Hermann Nirschl(Karlsruhe Institute of Technology), Jan-Hendrik Sommerling(Karlsruhe Institute of Technology), Claudia Duehrkop(University of Bern), Bo Nilsson(Uppsala University), Robbert J. Kok(Utrecht University), Ellen Hildebrandt(Karlsruhe Institute of Technology), Alberto Dessy(Abnoba (Germany))
Cited by 0
Related Papers
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.
|Journal of Biological Chemistry|1982|883
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?
|Stem Cells|2014|407
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?
|Stem Cells|2012|371